Guía Europea de Prevención Cardiovascular en la Práctica Clínica. Adaptación española del CEIPC 2008

  1. Lobos Bejarano, José María
  2. Royo Bordonada, Miguel Ángel
  3. Brotons Cuixart, Carlos
  4. Álvarez-Sala Walther, Luis Antonio
  5. Armario García, Pedro
  6. Maiques Galán, Antonio
  7. Mauricio Puente, Didac
  8. Sans Menéndez, Susana
  9. Villar Álvarez, Fernando
  10. Lizcano, Angel
  11. Gil Núñez, Antonio
  12. Álvaro Moreno, Fernando de
  13. Conthe Gutiérrez, Pedro
  14. Luengo, Emilio
  15. Río Ligorit, Alfonso del
  16. Cortés Rico, Olga
  17. Santiago Nocito, Ana María de
  18. Vargas, Miguel A.
  19. Martínez, Mercedes
  20. Lizarbe Alonso, Vicenta
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Year of publication: 2009

Volume: 21

Issue: 3

Pages: 124-150

Type: Article

More publications in: Clínica e investigación en arteriosclerosis


The present CEIPC Spanish adaptation of the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice 2008. This guide recommends the SCORE model for risk evaluation. The aim is to prevent premature mortality and morbidity due to CVD by means of dealing with its related risk factors in clinical practice. The guide focuses on primary prevention and emphasizes the role of the nurses and primary care doctors in promoting a healthy life style, based on increasing physical activity, changing dietary habits, and not smoking. The therapeutic goal is to achieve a Blood Pressure < 140/90 mmHg, but in patients with diabetes, chronic kidney disease, or definite CVD, the objective is < 130/80 mmHg. Serum cholesterol should be < 200 mg/dl and cLDL < 130 mg/dl, although in patients with CVD or diabetes, the objective is < 100 mg/dl (80 mg/dl if feasible in very high-risk patients). Patients with type 2 diabetes and those with metabolic syndrome must lose weight and increase their physical activity, and drugs must be administered whenever applicable, with the objective guided by body mass index and waist circumference. In diabetic type 2 patients, the objective is glycated haemoglobin < 7%. Allowing people to know the guides and developing implementation programs, identifying barriers and seeking solutions for them, are priorities for the CEIPC in order to put the recommendations into practice.